JP2001523236A - 純フルピルチンマレエート及びその変態aの製造方法 - Google Patents
純フルピルチンマレエート及びその変態aの製造方法Info
- Publication number
- JP2001523236A JP2001523236A JP54494098A JP54494098A JP2001523236A JP 2001523236 A JP2001523236 A JP 2001523236A JP 54494098 A JP54494098 A JP 54494098A JP 54494098 A JP54494098 A JP 54494098A JP 2001523236 A JP2001523236 A JP 2001523236A
- Authority
- JP
- Japan
- Prior art keywords
- flupirtine
- maleate
- pure
- modification
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000004048 modification Effects 0.000 title claims abstract description 50
- 238000012986 modification Methods 0.000 title claims abstract description 50
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 14
- DPYIXBFZUMCMJM-BTJKTKAUSA-N (z)-but-2-enedioic acid;ethyl n-[2-amino-6-[(4-fluorophenyl)methylamino]pyridin-3-yl]carbamate Chemical compound OC(=O)\C=C/C(O)=O.N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 DPYIXBFZUMCMJM-BTJKTKAUSA-N 0.000 title claims description 41
- 229960001655 flupirtine maleate Drugs 0.000 title claims description 40
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 54
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 53
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 238000003756 stirring Methods 0.000 claims description 21
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 20
- 239000011976 maleic acid Substances 0.000 claims description 20
- 238000006243 chemical reaction Methods 0.000 claims description 13
- 238000001556 precipitation Methods 0.000 claims description 13
- 238000005984 hydrogenation reaction Methods 0.000 claims description 9
- 238000000746 purification Methods 0.000 claims description 9
- 230000010933 acylation Effects 0.000 claims description 7
- 238000005917 acylation reaction Methods 0.000 claims description 7
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000007868 Raney catalyst Substances 0.000 claims description 5
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims description 5
- 229910000564 Raney nickel Inorganic materials 0.000 claims description 5
- 238000002425 crystallisation Methods 0.000 claims description 5
- 230000008025 crystallization Effects 0.000 claims description 5
- JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 claims description 4
- 229960003667 flupirtine Drugs 0.000 claims description 4
- 238000011065 in-situ storage Methods 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- -1 4-fluorobenzyl-amino Chemical group 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 239000012453 solvate Substances 0.000 description 22
- 239000013078 crystal Substances 0.000 description 19
- 230000009466 transformation Effects 0.000 description 15
- ZVCIIRBNNSUNCH-UHFFFAOYSA-N 6-n-[(4-fluorophenyl)methyl]-3-nitropyridine-2,6-diamine Chemical compound C1=C([N+]([O-])=O)C(N)=NC(NCC=2C=CC(F)=CC=2)=C1 ZVCIIRBNNSUNCH-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000011261 inert gas Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000006911 nucleation Effects 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 230000006181 N-acylation Effects 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- CKKXWJDFFQPBQL-UAIGNFCESA-N diazanium;(z)-but-2-enedioate Chemical compound [NH4+].[NH4+].[O-]C(=O)\C=C/C([O-])=O CKKXWJDFFQPBQL-UAIGNFCESA-N 0.000 description 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- AINBZKYUNWUTRE-UHFFFAOYSA-N ethanol;propan-2-ol Chemical compound CCO.CC(C)O AINBZKYUNWUTRE-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- PZILXGBGUICZBR-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]pyridin-2-amine Chemical compound C1=CC(F)=CC=C1CNC1=CC=CC=N1 PZILXGBGUICZBR-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- XTUSEBKMEQERQV-UHFFFAOYSA-N propan-2-ol;hydrate Chemical compound O.CC(C)O XTUSEBKMEQERQV-UHFFFAOYSA-N 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000000646 scanning calorimetry Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.2−アミノ−3−ニトロ−6−(4−フルオロベンジル−アミノ)−ピリジ ン(ANFP)をラネーニッケルの存在で水素化し、クロロギ酸エチルエステル でアシル化しかつ得られたフルピルチン−塩基をマレイン酸と反応させることに よって純フルピルチンマレエートを製造するに当たり、水素化、アシル化及び沈 殿を水溶性アルコール中で行うことを特徴とする、純フルピルチンマレエートの 製造方法。 2.アルコールとして好ましくはエタノール又はイソプロパノールを使用する、 請求項1記載の方法。 3.a)フルピルチン−粗製マレエートを単離しかつ結晶化によって純粋なマレ エートに変えるか又は b)現場で形成されたフルピルチン−塩基からマレイン酸との反応によってマ レエートを沈殿させかつ単離せずに純フルピルチンマレエートに変えるか又は c)フルピルチン−粗製塩基を沈殿させかつ再結晶し、次ぎにマレイン酸との 反応によってフルピルチン−純マレエートに変える 請求項1記載の方法。 4.反応を温度−10〜60℃で行う、請求項1から3までのいずれか1項記載 の方法。 5.請求項1から3までのいずれか1項記載の方法に より製造されたフルピルチンマレエートを場合により水を含有するイソプロパノ ール又はエタノール中で撹拌することを特徴とする、フルピルチンマレエートの 純粋な変態Aの製造方法。 6.撹拌工程を好ましくは結晶化されたフルピルチンマレエートを含有する請求 項3c)記載の反応混合物中で行う、請求項5記載の方法。 7.撹拌工程を温度−10〜60℃で行う、請求項5記載の方法。 8.請求項5記載の方法によって得られるフルピルチンマレエートの純粋な変態 A。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19716984A DE19716984A1 (de) | 1997-04-23 | 1997-04-23 | Verfahren zur Herstellung von reinem Flupirtin-Maleat und dessen Modifikation A |
DE19716984.8 | 1997-04-23 | ||
PCT/EP1998/002118 WO1998047872A1 (de) | 1997-04-23 | 1998-04-11 | Verfahren zur herstellung von reinem flupirtin-maleat und dessen modifikation a |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001523236A true JP2001523236A (ja) | 2001-11-20 |
JP4960538B2 JP4960538B2 (ja) | 2012-06-27 |
Family
ID=7827393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54494098A Expired - Fee Related JP4960538B2 (ja) | 1997-04-23 | 1998-04-11 | 純フルピルチンマレエート及びその変態aの製造方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US5959115A (ja) |
EP (1) | EP0977736B1 (ja) |
JP (1) | JP4960538B2 (ja) |
AR (1) | AR012597A1 (ja) |
AT (1) | ATE250579T1 (ja) |
AU (1) | AU7334698A (ja) |
DE (2) | DE19716984A1 (ja) |
DK (1) | DK0977736T3 (ja) |
ES (1) | ES2207832T3 (ja) |
PT (1) | PT977736E (ja) |
WO (1) | WO1998047872A1 (ja) |
ZA (1) | ZA983376B (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6821995B1 (en) | 1999-12-01 | 2004-11-23 | Duke University | Method of treating batten disease |
GB0613928D0 (en) | 2006-07-13 | 2006-08-23 | Pliva Istrazivanje I Razvoj D | Pharmaceutically acceptable salt and polymorphic forms |
WO2008110357A1 (en) * | 2007-03-12 | 2008-09-18 | Elbion Gmbh | Method for preparing a flupirtine maleate of a crystal modification b |
US20080279930A1 (en) * | 2007-05-07 | 2008-11-13 | Bernd Terhaag | Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof |
WO2009152142A1 (en) | 2008-06-09 | 2009-12-17 | Awd. Pharma Gmbh & Co. Kg | Sulfonate salts of flupirtine |
EP2346826A2 (en) | 2008-06-09 | 2011-07-27 | AWD.pharma GmbH & Co.KG | Carboxylic acid salts of 2-amino-3-carbethoxyamino-6-(4-fluoro-benzylamino)-pyridine |
DE102009023162B4 (de) | 2009-05-29 | 2011-07-07 | Corden PharmaChem GmbH, 68305 | Verfahren zur Herstellung von Flupirtin |
CN102140077A (zh) * | 2010-01-28 | 2011-08-03 | 范扶民 | 氟吡汀a晶型及其制备方法 |
WO2012004391A1 (en) * | 2010-07-09 | 2012-01-12 | K.H.S. Pharma Holding Gmbh | Process for the preparation of flupirtine maleate |
DE102010063612A1 (de) | 2010-12-20 | 2012-06-21 | Awd.Pharma Gmbh & Co. Kg | Neue Multikomponentenkristalle aus ([2-Amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamidsäureethylester und 2-[2-[(2,6-Dichlorphenyl)-amino]-phenyl]-essigsäure |
DE102010063609A1 (de) | 2010-12-20 | 2012-06-21 | Awd.Pharma Gmbh & Co. Kg | Neue Multikomponentenkristalle aus ([2-Amino-6-(4-fluoro-benzylamino)-pyridin-3yl)-carbamidsäureethylester und einer Arylpropionsäure |
CN102351786A (zh) * | 2011-11-01 | 2012-02-15 | 东南大学 | 一种氟吡汀丙二酸盐及其制备方法 |
WO2013080215A1 (en) | 2011-11-30 | 2013-06-06 | Arch Pharmalabs Limited | An improved process for the preparation of flupirtine and pharmaceutically acceptable salts thereof |
DE102015013478A1 (de) | 2015-10-17 | 2017-04-20 | Goethe-Universität | Neue Kristallphasen von Flupirtin-Maleat |
DE102017007385A1 (de) | 2017-08-02 | 2019-02-07 | Christoph Hoock | Maleatfreie feste Arzneimittelformen |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3133519A1 (de) * | 1980-09-13 | 1982-06-09 | Degussa Ag, 6000 Frankfurt | "2-amino-3-carbethoxyamino-6-(p-fluor-benzylamino)-pyridin-maleat" |
US4481205A (en) * | 1980-09-13 | 1984-11-06 | Degussa Aktiengesellschaft | 2-Amino-3-carbethoxyamino-6-(p-fluoro-benzylamino)-pyridine-maleate |
-
1997
- 1997-04-23 DE DE19716984A patent/DE19716984A1/de not_active Withdrawn
-
1998
- 1998-04-11 JP JP54494098A patent/JP4960538B2/ja not_active Expired - Fee Related
- 1998-04-11 DK DK98920511T patent/DK0977736T3/da active
- 1998-04-11 PT PT98920511T patent/PT977736E/pt unknown
- 1998-04-11 AT AT98920511T patent/ATE250579T1/de active
- 1998-04-11 DE DE59809728T patent/DE59809728D1/de not_active Expired - Lifetime
- 1998-04-11 AU AU73346/98A patent/AU7334698A/en not_active Abandoned
- 1998-04-11 WO PCT/EP1998/002118 patent/WO1998047872A1/de active IP Right Grant
- 1998-04-11 EP EP98920511A patent/EP0977736B1/de not_active Expired - Lifetime
- 1998-04-11 ES ES98920511T patent/ES2207832T3/es not_active Expired - Lifetime
- 1998-04-22 ZA ZA9803376A patent/ZA983376B/xx unknown
- 1998-04-23 US US09/064,790 patent/US5959115A/en not_active Expired - Lifetime
- 1998-04-23 AR ARP980101893A patent/AR012597A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PT977736E (pt) | 2004-02-27 |
WO1998047872A1 (de) | 1998-10-29 |
US5959115A (en) | 1999-09-28 |
ZA983376B (en) | 1998-07-03 |
EP0977736B1 (de) | 2003-09-24 |
AU7334698A (en) | 1998-11-13 |
JP4960538B2 (ja) | 2012-06-27 |
DE59809728D1 (de) | 2003-10-30 |
DK0977736T3 (da) | 2004-01-19 |
ATE250579T1 (de) | 2003-10-15 |
DE19716984A1 (de) | 1998-10-29 |
EP0977736A1 (de) | 2000-02-09 |
ES2207832T3 (es) | 2004-06-01 |
AR012597A1 (es) | 2000-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001523236A (ja) | 純フルピルチンマレエート及びその変態aの製造方法 | |
CN102020617B (zh) | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸的多晶型体及其制备方法 | |
TWI322805B (ja) | ||
KR101377778B1 (ko) | 엘트롬보팩 및 엘트롬보팩 염의 다형체 및 이의 제조 방법 | |
CN103804356A (zh) | 4-甲基-n-[3-(4-甲基-咪唑-1-基)-5-三氟甲基-苯基]-3-(4-吡啶-3-基-嘧啶-2-基氨基)-苯甲酰胺的晶形 | |
AU2017304887B2 (en) | Polymorphic forms of belinostat and processes for preparation thereof | |
NO146541B (no) | Fremgangsmaate for fremstilling av myke etyleniske polymerharpiksskum | |
JP3374155B2 (ja) | 保護−4−アミノメチル−ピロリジン−3−オンの製造方法 | |
CN114539216A (zh) | 沃诺拉赞的制备方法 | |
CN101228150B (zh) | 4-甲基-n-[3-(4-甲基-咪唑-1-基)-5-三氟甲基-苯基]-3-(4-吡啶-3-基-嘧啶-2-基氨基)-苯甲酰胺的晶形 | |
EP1603875B1 (en) | New process for preparing 4-aminomethyl-3-alkoxyiminopyrrolidine methanesulfonate | |
JP2002512223A (ja) | 純粋な鏡像体であるn−メチル−n−[(1s)−1−フェニル−2−((3s)−3−ヒドロキシピロリジン−1−イル)エチル]−2,2−ジフェニルアセトアミドの製造方法 | |
WO2015137407A1 (ja) | ヘテロアリールカルボン酸エステル誘導体の製造方法、その製造中間体及び結晶 | |
US20040010146A1 (en) | Process for the preparation imidazo[1,2-A]pyridine-3-acetamides | |
JP7344983B2 (ja) | ケノデオキシコール酸誘導体の調製方法 | |
JP7337279B2 (ja) | ピロリジニル尿素誘導体の調製方法 | |
US4804765A (en) | Process for synthesizing N-[(1'-allyl-2'pyrrolidinyl) methyl]2-methoxy-4,5-azimidobenzamide | |
JP3959178B2 (ja) | ヒドラジン誘導体の製造方法、その中間体および中間体の製造方法 | |
JP2692760B2 (ja) | ピロリジン誘導体及び製法 | |
JP3041444B2 (ja) | カルバジン酸誘導体の製造法 | |
CN114539220A (zh) | 一种富马酸沃诺拉赞中间体 | |
JP3499896B2 (ja) | 2’−デオキシヌクレオシド類の製造方法 | |
US8129413B2 (en) | Crystalline forms of MC4R agonist and process for synthesis | |
CN113185442A (zh) | 一种普拉西坦水合物晶体及其制备方法 | |
JPS58203999A (ja) | グルコ−ス化合物の製造法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050209 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20061115 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081111 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090202 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091110 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20101228 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110922 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110928 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111024 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111027 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111124 |
|
RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20111125 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111205 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20111125 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111226 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120323 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150330 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |